FDB (First Databank) vs Micromedex
The two drug knowledge incumbents, and almost nobody chooses between them the way this page implies, because most buyers already own both without knowing it: FDB sits inside the prescribing systems, Micromedex sits on the reference shelf. Where the comparison becomes real is when a health system asks which drug content it wants an AI product grounded in. Micromedex holds the stronger position on that question, because it is recognised as a drug compendium under United States federal law, which gives its content a standing in coverage decisions that no competitor's has, and it has a peer reviewed usability evaluation behind it. FDB holds the deeper distribution by far and the cleaner licensing architecture. Neither publishes a security attestation, a price, or any description of the model layer now being added on top of decades of curated content.
- Distribution nothing else in this index approaches. The drug databases are embedded inside the systems used by the majority of American hospitals, physician practices and pharmacies, so most interaction and dose warnings clinicians already see are built on this content.
- The historical arrangement is clean by design: content is licensed into customers' own systems, which places hosting, residency and processing questions with those customers rather than with the supplier.
- Its own newer products are framed conservatively, with a prescription agent producing orders explicitly for physician review and the verification product named as an assistant rather than a decision maker.
- It holds a regulatory status nothing else in this category has: recognition as a drug compendium under United States federal law, which means coverage and reimbursement decisions can reference it directly.
- The evidence position is stronger than most of this category, including a peer reviewed usability evaluation of the combined drug and disease product published in 2023 with authors from a major academic hospital.
- Every result carries a citation that opens the underlying source in one click, over a corpus curated from primary literature with in line referencing and daily updates, and integration is corroborated by structured third party customer feedback rather than only claimed.
Side by Side
| Axis | F FDB (First Databank) |
M Micromedex |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Neither vendor publishes a security attestation, trust centre, penetration testing statement or vulnerability disclosure programme, and neither publishes pricing, a pricing unit or a contract shape. FDB publishes no health privacy statement or business associate terms at all, which matters more now that its newer protocol server is described as serving drug knowledge in patient specific contexts rather than as static licensed content.
The exposure specific to FDB is concentration rather than discrimination: when one curated knowledge base sits underneath most medication decisions in a country, a gap or an error propagates everywhere at once, and no bias assessment, coverage analysis or governance documentation was located. Neither vendor describes its generative layer, its models or its evaluation method.